This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2011 Nov 22;9(1):5.

doi: 10.1038/nrclinonc.2011.174.

Drug therapy: a new standard for thyroid cancer?

Lisa Hutchinson

PMID: 22104984
DOI: 10.1038/nrclinonc.2011.174

Comment

Drug therapy: a new standard for thyroid cancer?

Lisa Hutchinson. Nat Rev Clin Oncol. 2011.

. 2011 Nov 22;9(1):5.

doi: 10.1038/nrclinonc.2011.174.

Author

Lisa Hutchinson

PMID: 22104984
DOI: 10.1038/nrclinonc.2011.174

No abstract available

PubMed Disclaimer

Comment on

Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial.
Wells SA Jr, Robinson BG, Gagel RF, Dralle H, Fagin JA, Santoro M, Baudin E, Elisei R, Jarzab B, Vasselli JR, Read J, Langmuir P, Ryan AJ, Schlumberger MJ. Wells SA Jr, et al. J Clin Oncol. 2012 Jan 10;30(2):134-41. doi: 10.1200/JCO.2011.35.5040. Epub 2011 Oct 24. J Clin Oncol. 2012. PMID: 22025146 Free PMC article. Clinical Trial.

References

1. J Clin Oncol. 2012 Jan 10;30(2):134-41 - PubMed

Publication types

Actions

LinkOut - more resources

Full Text Sources
- Nature Publishing Group
- Ovid Technologies, Inc.